Standout Papers
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer (2016)
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater (2019)
- Volatile Organic Compounds of Lung Cancer and Possible Biochemical Pathways (2012)
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50% (2021)
- Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges (2018)
Immediate Impact
3 by Nobel laureates 3 from Science/Nature 83 standout
Citing Papers
Applied body-fluid analysis by wearable devices
2024 StandoutNature
Glycan-specific molecularly imprinted polymers towards cancer diagnostics: merits, applications, and future perspectives
2024 Standout
Works of Nir Peled being referenced
Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
2018 Standout
Silicon Nanowire Sensors Enable Diagnosis of Patients via Exhaled Breath
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Nir Peled | 8682 | 9957 | 2292 | 296 | 17.2k | |
| Harvey I. Pass | 17764 | 7521 | 8113 | 568 | 31.2k | |
| Carlo Riccardo Rossi | 2218 | 4576 | 3061 | 482 | 13.4k | |
| Dong M. Shin | 5165 | 8465 | 9950 | 356 | 26.1k | |
| James M. Reuben | 3002 | 9014 | 3637 | 239 | 15.7k | |
| Jan P. van Meerbeeck | 10705 | 5518 | 2478 | 371 | 15.1k | |
| Gerardo Botti | 2100 | 6523 | 5095 | 538 | 14.5k | |
| Simone Mocellin | 2266 | 5085 | 3125 | 272 | 11.4k | |
| Gerhard Ehninger | 1764 | 6426 | 6007 | 677 | 24.5k | |
| Michael J. O’Brien | 8550 | 12078 | 1707 | 213 | 17.6k | |
| Alexander Stojadinovic | 2401 | 3549 | 2271 | 256 | 12.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...